Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

Over the past decade, immunotherapy delivered novel treatments for many cancer types. However, lung cancer still leads cancer mortality, and non-small-cell lung carcinoma patients with mutant EGFR cannot benefit from checkpoint inhibitors due to toxicity, relying only on palliative chemotherapy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Vicencio, J. M., Evans, R., Green, R., An, Z., Deng, J., Treacy, C., Mustapha, R., Monypenny, J., Costoya, C., Lawler, K., Ng, K., De-Souza, K., Coban, O., Gomez, V., Clancy, J., Chen, S. H., Chalk, A., Wong, F., Gordon, P., Savage, C., Gomes, C., Pan, T., Alfano, G., Dolcetti, L., Chan, J. N. E., Flores-Borja, F., Barber, P. R., Weitsman, G., Sosnowska, D., Capone, E., Iacobelli, S., Hochhauser, D., Hartley, J. A., Parsons, M., Arnold, J. N., Ameer-Beg, S., Quezada, S. A., Yarden, Y., Sala, G., Ng, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960767/
https://www.ncbi.nlm.nih.gov/pubmed/35347108
http://dx.doi.org/10.1038/s41419-022-04701-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960767/
https://www.ncbi.nlm.nih.gov/pubmed/35347108
http://dx.doi.org/10.1038/s41419-022-04701-3

Ejemplares similares